問卷

TPIDB > Search Result

Search Result

篩選

List

1858Cases

2020-01-01 - 2024-12-25

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

-

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

2018-08-01 - 2022-06-30

Others

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2018-02-01 - 2024-12-31

Phase II

Active
A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia
  • Condition/Disease

    Parkinson′s disease dementia

  • Test Drug

    ceftriaxone

Participate Sites
11Sites

Recruiting5Sites

Terminated5Sites

2025-01-26 - 2027-01-26

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-06-01 - 2027-12-31

Phase I

Active
A Phase 1, First-in-Human, Open-label, Dose- escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 in Subjects with Advanced Solid Tumors
  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    injection

Participate Sites
3Sites

Recruiting3Sites

2024-03-13 - 2028-03-13

Phase I

Active
A Phase I Open-label Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LXP1788 Injection in Patients with Advanced Solid Tumors.
  • Condition/Disease

    Solid Tumor Malignancies, Cancer

  • Test Drug

    注射劑

Participate Sites
2Sites

Recruiting2Sites

2020-05-18 - 2023-12-31

Phase III

Active
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated Recurrent Urinary Tract Infections (rUTIs) in Women
  • Condition/Disease

    Recurrent Urinary Tract Infections (rUTIs)

  • Test Drug

    U101

Participate Sites
19Sites

Not yet recruiting7Sites

Recruiting6Sites

Terminated6Sites

2018-12-06 - 2025-12-31

Phase II

Active
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients with Advanced Neuroendocrine Tumors
  • Condition/Disease

    Neuroendocrine Tumors

  • Test Drug

    CVM-1118

Participate Sites
8Sites

Recruiting4Sites

Terminated3Sites

2025-11-03 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites